Market Overview:

The Exosomes Market size is estimated to reach $1.2 billion by 2030, growing at a CAGR of 30% during the forecast period 2024-2030, according to a recent report published by IndustryARC, titled, “Exosomes Market Size, Share & Trends Analysis Report- By Product (Apparatuses, Gears, and Reactants/Reagents), By Cancer Application (Kidney Cancer, Thyroid Cancer, Prostate Cancer, HCC (Hepatocellular Carcinoma) Liver Cancer, Breast Cancer, Lung Cancer, Throat Cancer), By End User (Hospitals, Pharmaceutical Firms, Research Bodies/Institutions, Testing Clinics), By Geography - Global Opportunity Analysis & Industry Forecast, 2024-2030”
The technological breakthrough in isolating exosomes and other practices and the enlarging population and cases of cancer are fueling the growth of the Exosomes industry during the forecast period.

North America Dominated the Market in 2023:

In 2023, North America emerged as the largest market, capturing 35% of the overall market share. This dominance can be attributed to several key factors, including a robust economy that facilitates significant investments in research laboratories equipped with world-class facilities. The presence of prestigious institutions such as MIT and Harvard further enhance the region's research capabilities. Additionally, the U.S. government allocates approximately 5% of its annual medical budget to research and development, fostering innovation and growth within the sector. These elements collectively contribute to North America's leading position in the market landscape. 

Exosomes Market: Key Takeaways

The Technological Breakthrough in Isolating Exosomes and Other Practices is Driving the Market Growth:

In 2023, the Pan American Health Organization (PAHO) reported approximately 20 million diagnosed cancer cases and around 10 million deaths globally. As cancer prevalence rises, researchers are developing innovative tools and techniques to combat this issue. Notably, exosomes extracted from cow's milk have shown potential in treating breast and lung cancers. This advancement has led to an increasing demand for exosome-based medical treatments, reflecting a growing interest in harnessing biological materials for therapeutic purposes. The focus on exosomes underscores the ongoing efforts to improve cancer care and patient outcomes worldwide.

For More Queries About "Exosomes Market " @ https://www.industryarc.com/pdfdownload.php?id=504033

Market Growth Driven by an Enlarging Population and Cases of Cancer:

The global population, particularly the elderly, is rapidly increasing. The World Health Organization (WHO) projects that by 2030, one-sixth of the global population will be aged 60 or older, rising from 1 billion in 2020 to 1.4 billion. By 2050, this demographic is expected to double to 2.1 billion, with those aged 80 and above tripling to 426 million. Aging often brings health challenges, including weakened immunity and increased susceptibility to diseases like cancer, driving demand for exosome therapies. Additionally, failed clinical trials can cost between $800 million and $1.4 billion, highlighting the economic stakes involved in healthcare advancements. 

Scope of the Report: 

Report Metric 

Details 

Base Year Considered

2023

Forecast Period

2024–2030

CAGR

30%

Market Size in 2030

$1.2 billion

Segments Covered

By Product, By Cancer Application, By End User, and By Region

Geographies Covered

North America (USA, Canada, and Mexico), Europe (UK, Germany, France, Italy, Netherlands, Spain, Russia, and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, Malaysia, and Rest of APAC), South America (Brazil, Argentina, Colombia, Chile, and Rest of South America), and Rest of the World (Middle East, and Africa).

Key Market Players

  1. Danaher Beckman Coulter Inc.

  2.  QIAGEN

  3.  ExoDx

  4.  MBL International

  5.  Novus Biologicals

  6.  Lonza

  7.  System Biosciences

  8.  Miltenyi Biotec

  9.  Thermo Fisher Scientific Inc.

  10.  Everzom


Recent Developments:
  • In June 2023, Evox Therapeutics Ltd acquired Codiak Biosciences' engEx-AAV™ technology platform, securing exclusive rights to engineering and manufacturing, enabling active loading of adeno-associated virus (AAV) into exosomes for enhanced delivery and expression in pre-clinical models, while shielding from neutralizing antibodies.

Exosomes Market: Competitive Landscape

Key companies profiled in the Exosomes Market are Danaher Beckman Coulter Inc., QIAGEN, ExoDx, MBL International, Novus Biologicals, Lonza, System Biosciences, Miltenyi Biotec, Thermo Fisher Scientific Inc., Everzom, and others.

About IndustryARC™:

IndustryARC primarily focuses on Market Research and Consulting Services specific to Cutting Edge Technologies and Newer Application segments of the market. The company’s Custom Research Services are designed to provide insights into the constant flux in the global demand-supply gap of markets. 
 
IndustryARC’s goal is to provide the right information required by the stakeholder at the right point in time, in a format that assists an intelligent and informed decision-making process.

Contact Us:

Mr. Venkat Reddy
IndustryARC
USA: (+1) 518-282-4727